Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Detemir + OADs in T2DM
NCT00592527Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2004
- Primary completion
- Dec 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of insulin detemir in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoint: Glycated Hemoglobin A1c at 20 weeks. Started Apr 2004; status: completed.
02
Drugs
insulin detemir
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00592527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00592527.